We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Tracking System for Spinal Tumors

By HospiMedica staff writers
Posted on 07 Jul 2005
A new spine-tracking system has been integrated with a radiosurgery system to eliminate the need for surgical implantation of radiographic markers, or fiducials, in the delivery of radiosurgery treatments for spinal tumors.

Spinal radiosurgery has posed problems for oncologists and neurosurgeons. More...
Traditional radiation treatments may not be accurate because of the close proximity to sensitive structures like the spinal cord. Also, because skeletal structures such as spinal vertebra move independently, doctors found it necessary to surgically implant fiducials into the spine in order to track the movement of the lesion during treatment, which introduced many of the drawbacks associated with invasive surgery.

The CyberKnife radiosurgery system is the only system that continually tracks lesions and automatically compensates for their movements throughout the entire treatment. It can deliver submillimeter total clinical accuracy in the spine without fiducials, thereby offering precision and conformality. The tracking system, called Xsight, is the product of Accuray (Sunnyvale, CA, USA), as is the CyberKnife. Xsight helps to treat lesions throughout the spinal region, including cervical, thoracic, lumbar, and sacral tumors.

"Xsight obviates the need for placement of fiducials and allows for computerized real-time tracking and delivery of radiation with submillimeter accuracy,” noted Fraser Henderson, M.D., director, Spine Tumor Center (Georgetown University Hospital, Washington, DC, USA). "This is a significant advance in eliminating pain for the patient and for allowing the surgeon to expedite treatment within the limited therapeutic window.”




Related Links:
Accuray

Gold Member
POC Blood Gas Analyzer
Stat Profile Prime Plus
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Ultrasound Needle Guidance System
SonoSite L25
VTE Prevention System
Flowtron ACS900
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.